Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma-Reference-Cited by-同舟云学术

Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Published:2023-07-28 Issue:S6 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Castellino Sharon M.¹^ORCID,Giulino‐Roth Lisa²,Harker‐Murray Paul³,Kahn Justine M.⁴^ORCID,Forlenza Christopher⁵,Cho Steve⁶,Hoppe Bradford⁷^ORCID,Parsons Susan K.⁸,Kelly Kara M.⁹,

Affiliation:

1. Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta/Department of Pediatrics Emory University School of Medicine Atlanta Georgia USA

2. Department of Pediatrics Weill Cornell Medical College New York New York USA

3. Pediatric Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

4. Division of Pediatric Hematology Oncology and Stem Cell Transplantation Columbia University Medical Center New York New York USA

5. Department of Pediatrics Memorial Sloan‐Kettering Cancer Center New York New York USA

6. Department of Radiology University of Wisconsin/University of Wisconsin Carbone Comprehensive Cancer Center Madison Wisconsin USA

7. Department of Radiation Oncology Mayo Clinic Jacksonville Florida USA

8. Department of Medicine Tufts University School of Medicine/Department of Pediatrics Reid R. Sacco AYA Cancer Program/Division of Hematology/Oncology Tufts University School of Medicine/Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston Massachusetts USA

9. Department of Pediatric Oncology Roswell Park Comprehensive Cancer Center/Department of Pediatrics University at Buffalo Jacobs School of Medicine and Biomedical Sciences Buffalo New York USA

Abstract

AbstractThe goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials include: (i) superior event‐free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high‐risk disease, (ii) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and (ii) the potential to select a population that can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead a National cancer Institute National Clinical Trials Network phase 3 trial to evaluate the combination of Bv/nivolumab in early‐stage disease. Ongoing advances in technology and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.

Funder

St. Baldrick's Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30580

Reference76 articles.

1. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study

2. U.S. Cancer Statistics Working Group.U.S. Cancer Statistics Data Visualizations Tool based on 2021 submission data (1999–2019): U.S.Department of Health and Human Services Centers for Disease Control and Prevention and National Cancer Institute;June2022. Accessed May 30 2023.https://gis.cdc.gov/Cancer/USCS/#/Demographics/

3. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.